Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 131 of the 132 references it cites were found in a registry or an index; 79 of the 113 sources its claims cite were checked for support.

The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry

Open access
Montel Hayes, Rachel, Mason, Christopher E., Miller, John J. · 2025 · Frontiers in Psychiatry

Abstract

The etiology of psychiatric disorders is complex, involving both genetic and environmental factors with emerging evidence suggesting that epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, significantly contribute to mental health. The epigenome influences the development of psychiatric disorders and human behavior and may be considered in clinical observations. Epigenetic changes have been well-established in BDNF , COMT , FKBP5 , NR3C1 , SLC6A4 , and DRD2 , genes associated with psychiatric disorders, including schizophrenia, major depressive disorder (MDD), bipolar disorder (BP), post-traumatic stress disorder (PTSD), and autism spectrum disorder (ASD). Therefore, these epigenetic marks have the potential to be suitable biomarkers for diagnostics, as predictors of prognosis, and for the development of personalized treatments. By exploring the role of clinically relevant epigenetic genes, we review the role of the epigenome in the context of psychiatric disorders and human behavior; and we consider that these changes may be observed in the context of precision psychiatry. This review synthesizes findings from over 100 original research articles and reviews spanning a range of clinical studies. Despite promising associations, challenges in the onset of precision psychiatry, such as tissue heterogeneity, small sample sizes, and lack of replication, are likely to limit translation into clinical practice. Future research in precision psychiatry will help identify clinically actionable epigenetic biomarkers, ushering in an era of genomic medicine in psychiatry.

Overview

CoChat Summary

TL;DR

This narrative review summarizes epigenetic mechanisms—DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling—and their roles in psychiatric disorders, focusing on BDNF, COMT, FKBP5, NR3C1, SLC6A4, and DRD2. It argues these marks may support precision psychiatry as biomarkers for diagnosis, prognosis, and treatment response, but translation is limited by tissue heterogeneity, small samples, lack of replication, and other methodological challenges.

Key findings

  • Epigenetic changes are well-established in BDNF, COMT, FKBP5, NR3C1, SLC6A4, and DRD2 and are associated with schizophrenia, MDD, bipolar disorder, PTSD, ASD, ADHD, OCD, AUD, and SUD. Examples include BDNF promoter hypermethylation reducing BDNF expression, NR3C1 exon 1F hypermethylation after childhood adversity impairing glucocorticoid receptor/HPA-axis regulation, and FKBP5 demethylation/upregulation linked to stress reactivity.
  • Epigenetic marks have potential clinical utility as biomarkers for diagnostics, prognosis, relapse risk, and personalized treatment. The review states that methylation of NR3C1, BDNF, and FKBP5 may differentiate subtypes of MDD, PTSD, or schizophrenia; low BDNF methylation correlates with better SSRI response, and high NR3C1 methylation predicts poorer CBT response in PTSD.
  • Experimental epigenetic therapies include HDAC inhibitors such as valproic acid, sodium butyrate, and Vorinostat (SAHA); BET inhibitor JQ1; miRNA-based therapies involving miR-124, miR-132, miR-135, and miR-146a; and CRISPR/dCas9 epigenetic editing approaches, mostly in preclinical models.
  • The review synthesizes findings from over 100 original research articles and reviews. It concludes that challenges such as tissue heterogeneity, small sample sizes, and lack of replication are likely to limit translation into routine clinical practice.

Methods

  • Narrative review of clinically relevant epigenetic mechanisms, candidate genes, and precision psychiatry applications.
  • The paper states it synthesizes findings from over 100 original research articles and reviews spanning a range of clinical studies.
  • No primary data collection or systematic quantitative synthesis is reported; the review summarizes mechanistic, candidate-gene, and clinical-implication literature.

Limitations

  • Stated: limited access to brain tissue means sampling often relies on blood, saliva, or postmortem samples that may not reflect CNS changes; cell-type specificity and bulk tissue analyses can obscure cellular differences; epigenetic marks are dynamic and temporally variable; different assays can yield inconsistent results; large-scale reference datasets are predominantly from individuals of European ancestry; confounders include lifestyle, socioeconomic factors, substance use, and comorbid medical conditions; epigenetic findings are not yet validated for routine psychiatric practice; and an exclusive focus on epigenetics risks oversimplifying disease etiology.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, formal study-quality assessment, or quantitative meta-analysis, which limits reproducibility and strength of conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2025.1671122

Cites

131 of 132 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

53 Valid · 16 Not valid · 29 Not checked · 20 Own results and interpretations

77 more claims · 45 with their cited sources checked

Create a free account to see all 118 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 4
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 131 references

Cited by

See all 5

Metadata

Authors
Montel Hayes, R., Mason, C. E., & Miller, J. J.
Affiliations
Cornell University (US)
Venue
Frontiers in Psychiatry
Published
2025-10-29
Volume
16
Pages
1671122-1671122
ISSN
1664-0640 (ISSN-L)
OpenAlex
W4415663958
Cited by
5
References
131
Citations by year
2026: 5
FWCI
0.44
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
epigenetics, mental illness, precision psychiatry, DNA methylation, histone modifications, non-coding RNA, candidate genes, brain-derived neurotrophic factor, catechol-O-methyltransferase, FKBP5, NR3C1, serotonin transporter, DRD2, schizophrenia, major depressive disorder, bipolar disorder, post-traumatic stress disorder, autism spectrum disorder, epigenetic biomarkers, personalized treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry. https://app.cochat.ai/papers/10.3389/fpsyt.2025.1671122
The paper
Montel Hayes, R., Mason, C. E., & Miller, J. J. (2025). The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1671122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.